Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004 - 2010

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 3, 2011, Pages 399-416

  Singh, Inder Pal ^a   Chauthe, Siddheshwar Kisan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

AIDS; CCR5; chemokine receptor; CXCR4; HIV

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 5 [[2 (4 BENZOYL 2 METHYLPIPERAZIN 1 YL) 1 METHYL 2 OXOETHYL]OXY] 4 METHOXYPYRIDINE 2 CARBOXYLIC ACID METHYLAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARGANINE C; AZOLOPIPERAZINE DERIVATIVE; BENZOTHIAZOLE; BMS 705; BREVIFOLIN CARBOXYLIC ACID; CORILAGIN; CYCLOTRIAZADISULFONAMIDE; DIKETO AZOLOPIPERIDINE DERIVATIVE; ENFUVIRTIDE; GERANIIN; HUMAN IMMUNODEFICIENCY VIRUS ATTACHMENT INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; N PHENYL N PIPERIDIN 4 YL OXALAMIDE DERIVATIVE; NB 2; NB 206; NB 64; NBD 556; NBD 557; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; REPANDUSINIC ACID; T 2635; TETRAHYDROCARBOLINE DERIVATIVE; TIEGHEMELIN; TIFUVIRTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS TRANSMISSION;

DRUG DISCOVERY; HIV FUSION INHIBITORS; PATENTS AS TOPIC; PRODRUGS; TIME FACTORS;

EID: 79952063519     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.550876     Document Type: Review

References (71)

1. Sattentau QJ, Moore JP. The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci 1993;342:59-66
2. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999;7:144-49 (Pubitemid 29229899)
3. Callahan LN, Phelan M, Mallinson M, Norcross MA. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991;65:1543-50
4. Dey B, Lerner DL, Lusso P, et al Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000;74:4562-69 (Pubitemid 30237881)
5. Rusconi S, Moonis M, Merrill DP, et al Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996;40:234-36 (Pubitemid 26020755)
6. Huang L, Chen CH. Molecular targets of anti-HIV-1 triterpenes. Curr Drug Targets Infect Disord 2002;2:33-6 (Pubitemid 34649853)
7. Mastrolorenzo A, Maresca A, Rusconi S, Supuran CT. Update on the development of HIV entry inhibitors. Future HIV Ther 2008;2:479-507
8. De Clercq E. Targets and strategies for the antiviral chemotherapy of AIDS. Trends in Pharmacol Sci 1990;11:198-205 (Pubitemid 20139305)
9. Jacobson JM, Israel RJ, Lowy I, et al Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48:423-29 (Pubitemid 38141697)
10. Moore JP, Sattentau QJ, Klasse PJ, Burkly LC. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992;66:4784-93
11. De Clercq E. Molecular targets for antiviral agents. J Pharmacol Exp Ther 2001;297:1-10 (Pubitemid 32242557)
12. Singh IP, Chauthe SK. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010. Expert Opin Ther Patents 2011;21:229-71
13. Wang T, Zhang Z, Wallace OB, et al Discovery of 4-benzoyl-1-[(4-methoxy- 1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]- 2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003;46:4236-39 (Pubitemid 37153004)
14. Si Z, Madani N, Cox JM, et al Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004;101:5036-41 (Pubitemid 38469198)
15. Lin PF, Blair W, Wang T, et al A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003;100:11013-18 (Pubitemid 37140144)
16. Bristol-Myers Squibb Company. Preparation and pharmaceutical compositions of indole, azaindole and related heterocyclic 4-alkenyl piperidine amides. US7348337; 2004
17. Bristol-Myers Squibb Company. Preparation of alkene piperidine derivatives as antiviral agents useful for the treatment of HIV and AIDS. US7572810; 2007
18. Bristol-Myers Squibb. Preparation of indolyl-, azaindolyl-, and related heterocyclic sulfonylureidopiperazines for treatment of HIV and AIDS. WO2004000210; 2004
19. Bristol-Myers Squibb Company. Preparation of benzothiazole antiviral agents for treating HIV infection. US7087610; 2005
20. Bristol Myers Squibb. Preparation of benzothiazole antiviral agents for treating HIV infection. US20050272734; 2005
21. Bristol-Myers Squibb Company. Preparation of piperazine enamines as antiviral agents useful for the treatment of HIV and AIDS. US7504399; 2007
22. Bristol-Myers Squibb Company. Preparation of piperazine amidines as antiviral agents. US7396830; 2007
23. Bristol-Myers Squibb Company. Preparation of tetrahydrocarbolines for treatment of HIV infection and AIDS. US7449476; 2005
24. Bristol-Myers Squibb Company. Preparation of 3-(piperazin-1-yl)cyclobut- 3-ene-1,2-dione derivatives as antiviral agents. US7501419; 2007
25. Bristol-Myers Squibb Company. Diketo azolopiperidines and azolopiperazines as anti-HIV agents. WO2009158394; 2009
26. Bristol Myers Squibb Company. Diketopiperidine derivatives as HIV attachment inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection and AIDS. WO2009158396; 2009
27. Bristol Myers Squibb Company. Prodrugs based on bicyclic nitrogen-containing heterocyclic antiviral agents having substituted piperazine or piperidine rings. WO2005090367; 2005
28. Bristol-Myers Squibb Company. Preparation of aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents. US7183284; 2006
29. Bristol Myers Squibb Company. Methods of treating HIV infection. US2005215543; 2005
30. Bristol Myers Squibb Company. Combination for the treatment of AIDS or HIV infection. WO2005102391; 2005
31. Wang J, Le N, Heredia A, et al Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. Org Biomol Chem 2005;3:1781-86 (Pubitemid 40683106)
32. Pfizer Limited. Piperazine derivatives for the treatment of HIV infections. WO2005016344; 2005
33. Pfizer Limited. Piperazine and piperidine derivatives as anti-HIV agents. WO2005121094; 2005
34. Pfizer, Inc. Preparation of piperazine derivatives for use in pharmaceutical compositions for the treatment of HIV infection. US2005043300; 2005
35. Pfizer, Inc. Preparation of a crystalline form of 5-[[(1S)-2-((2R)-4- benzoyl-2- methylpiperazin-1-yl)-1-methyl-2- oxoethyl]oxy]-4-methoxypyridine-2- carboxylic acid methylamide for the treatment of HIV. WO2006085199; 2006
36. Propharmacon, Inc. N-Aryl piperidine compounds for inhibiting HIV infection. WO2005120503; 2005
37. Trimeris, Inc. Piperazine and piperidine biaryl derivatives. WO2007103456; 2007
38. Lu RJ, Tucker JA, Zinevitch T, et al Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group. J Med Chem 2007;50:6535-44 (Pubitemid 350309093)
39. Zhao Q, Ma L, Jiang S, et al Identification of N-phenyl-N-(2,2,6,6- tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005;339:213-25 (Pubitemid 41169789)
40. Johns Hopkins University. Small molecule CD4 mimetics and uses thereof. WO2010053583; 2010
41. Madani N, Schon A, Princiotto AM, et al Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008;16:1689-701
42. Vermeire K, Zhang Y, Princen K, et al CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002;302:342-53 (Pubitemid 35373862)
43. Bell TW, Anugu S, Bailey P, et al Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 2006;49:1291-312 (Pubitemid 43271884)
44. Vermeire K, Bell TW, Choi HJ, et al The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003;63:203-10 (Pubitemid 36043824)
45. Genzyme Corp. Preparation of piperidine derivatives as modulators of chemokine receptor in particular CCR5 receptor. WO2008070758; 2008
46. Phytrix JV. Phyllanthus extract for prevention and/or treatment of a HIV-associated disease. EP2116253; 2009
47. John Hopkins University. Combinational paradigm combating HIV, HIV/HSV, or HIV/HPV infections in humans using small molecular weight compounds from plants. WO2008088806; 2008
48. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73 (Pubitemid 27199898)
49. Jiang S, Debnath AK. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. Biochem Biophys Res Commun 2000;269:641-6 (Pubitemid 30440354)
50. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998;95:15613-17 (Pubitemid 29018748)
51. Wild C, Oas T, McDanal C, et al A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-41
52. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3
53. Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-47 (Pubitemid 41671913)
54. Weiss CD. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev 2003;5:214-21 (Pubitemid 38258384)
55. LaBranche CC, Galasso G, Moore JP, et al HIV fusion and its inhibition. Antiviral Res 2001;50:95-115 (Pubitemid 32441825)
56. Dwyer JJ, Wilson KL, Davison DK, et al Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007;104:12772-7 (Pubitemid 47255230)
57. Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 1999;42:3203-9 (Pubitemid 29409709)
58. Jiang S, Debnath AK. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem Biophys Res Commun 2000;270:153-7 (Pubitemid 30440408)
59. Zhao Q, Ernst JT, Hamilton AD, et al XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 2002;18:989-97
60. Jiang S, Lin K, Zhang L, Debnath AK. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999;80:85-96 (Pubitemid 29248906)
61. New York Blood Center. Substituted N-phenylpyrrole compounds forinhibition of HIV infection by blocking HIV entry. WO2004047730; 2004
62. New York Blood Center. Compounds for inhibition of HIV infections by blocking HIV entry. US2007232684; 2007
63. New York Blood Center. Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds. US20060287319; 2006
64. New York Blood Center. Anti-viralcompositions comprising heterocyclic substituted phenyl furans and related compounds. WO2006138118; 2006
65. New York Blood Center. Combination therapy of HIV fusion/entry inhibitors targeting gp41. WO2010019717; 2010
66. New York Blood Center. Starch-pomegranate juice complex as an HIV entry inhibitor and topical microbicide. US20060062866; 2006
67. New York Blood Center. Methods for preventing HIV-1 or HIV-2 infection. US6727240; 2004
68. President and Fellows of Harvard College. HIV inhibitors. WO2008030803; 2008
69. University of Southern Medical. 1¢¢,2¢¢, 3¢¢,7¢¢-tetrahydrotheaflavin with anti-AIDS effects. CN101475556; 2009
70. University of Southern Medical Preparation of 1¢¢, 2¢¢,3¢¢,7¢¢- tetrahydrotheaflavin-3,3¢- bisgallate as anti-AIDS agent. CN10147555; 2009 . This patent discloses the gp41 inhibitory activity of tea polyphenols.
71. Secretary of the Department of Health and Human Services of United States. Methods for inhibiting HIV and other viral infections by modulating ceramide metabolism. WO2005072091; 2005